SCHEMBL14720569

SCHEMBL14720569

COC1CCCCC(O)(c2ccc(C=C3CCN(C4CCC4)CC3)cc2)C1

nearest known ligand 0.34

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.34
DRD1 P21728 5/20 0.32
DRD2 P14416 4/20 0.32
SRD5A2 P31213 2/20 0.31
CYP2D6 P10635 1/20 0.31
SLC18A3 Q16572 1/20 0.31
CCR1 P32246 1/20 0.30
MAPK1 P28482 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14721390 0.97 DRD1 (0.33) HRH3DRD1DRD2SRD5A2CYP2D6
SCHEMBL14720799 0.89 HRH3 (0.32) HRH3SLC18A3CCR1
SCHEMBL14720519 0.88 HRH3 (0.34) HRH3SLC18A3CCR1
SCHEMBL14721393 0.88 HRH3 (0.36) HRH3SRD5A2SLC18A3CCR1
SCHEMBL14721332 0.86 HRH3 (0.39) HRH3SRD5A2SLC18A3CCR1
SCHEMBL14720774 0.85 HRH3 (0.40) HRH3SRD5A2SLC18A3CCR1
SCHEMBL14720610 0.85 HRH3 (0.32) HRH3SRD5A2SLC18A3CCR1
SCHEMBL14720611 0.85 HRH3 (0.32) HRH3SRD5A2SLC18A3CCR1
SCHEMBL14721517 0.85 HRH3 (0.32) HRH3SRD5A2SLC18A3CCR1
SCHEMBL14721355 0.82 HRH3 (0.35) HRH3SRD5A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013027001-A1 COMPOUNDS AND THEIR USE TO TREAT HISTAMINE H3 RELATED DISORDERS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-02-28 WO claimed
WO-2013027001-A1 COMPOUNDS AND THEIR USE TO TREAT HISTAMINE H3 RELATED DISORDERS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-02-28 WO disclosed
WO-2013027001-A1 COMPOUNDS AND THEIR USE TO TREAT HISTAMINE H3 RELATED DISORDERS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-02-28 WO disclosed